All In Biotech

Drug Trial Radar · NCT07196774

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

A Randomized, Open-label, Multicenter Phase III Study of SHR-A1811 Compared to Docetaxel+Carboplatin+Trastuzumab+Pertuzumab as a Neoadjuvant Therapy for the Initial Treatment of Early-stage or Locally Advanced HER2-positive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 740 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

740

Actual

Start

Oct 23, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, open-label, parallel Phase III clinical trial. 650 early-stage or locally advanced breast cancer participants will be enrolled and randomly assigned to SHR-A1811 monotherapy group (trial group) or TCbHP treatment group (control group) at a 1:1 ratio. Participants will receive neoadjuvant treatments of SHR-A1811 or TCbHP, while those who have completed neoadjuvant therapy and are suitable for surgery must undergo surgical treatment. The participants will be evaluated on tumor efficacy through postoperative pathological assessment by IRC and pathologists from the research center. The primary endpoint will be tpCR evaluated by IRC. Participants who complete surgical treatment will be followed up for at least 3 years at study endpoints such as EFS, DFS, and DDFS.

Conditions

  • Early-stage or Locally Advanced HER2-positive Breast Cancer

Interventions

  • SHR-A1811 for InjectionDrug

    SHR-A1811 for injection.

  • Docetaxel injectionDrug

    Docetaxel injection.

  • Trastuzumab InjectionDrug

    Trastuzumab injection.

  • Carboplatin for InjectionDrug

    Carboplatin for injection.

  • Pertuzumab InjectionDrug

    Pertuzumab injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative total pathologic complete response (tpCR) evaluated by Independent Review Committee (IRC) after finishing neoadjuvant treatments.Time frame: From the enrollment of the first subject to the end of the study, it lasted about 36 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shengjing Hospital, China Medical University

    Shenyang, Liaoning, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.